Search research articles
Contact Us
Filters
Showing results (81-90 of 93) with videos related to
Page
of 10
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
February 26, 2026
Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG study
Lea Jessica Albrecht, Jana Garnier, Anne Zaremba, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2025
Long-Term Follow-Up of Real-World Adjuvant Anti-PD-1 Checkpoint Inhibition and Targeted Therapy in Patients With Stage III Melanoma
Georg C Lodde, Jessica C Hassel, Imke von Wasielewski, et al.
Ebiomedicine
|
September 3, 2023
Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma - analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM
Jan-Malte Placke, Mona Kimmig, Klaus Griewank, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 8, 2021
Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases
Anne Zaremba, Manuel Philip, Jessica C Hassel, et al.
EMBO Reports
|
September 26, 2022
MCU controls melanoma progression through a redox-controlled phenotype switch
Ioana Stejerean-Todoran, Katharina Zimmermann, Christine S Gibhardt, et al.
Nature Cancer
|
July 31, 2023
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma
Renáta Váraljai, Lisa Zimmer, Yahya Al-Matary, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 30, 2024
Early versus late response to PD-1-based immunotherapy in metastatic melanoma
Georg C Lodde, Fang Zhao, Rudolf Herbst, et al.
Journal for Immunotherapy of Cancer
|
June 10, 2022
Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG
Cindy Franklin, Peter Mohr, Leonie Bluhm, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 1, 2025
Sex-specific survival in advanced metastatic melanoma - a DeCOG study on 2032 patients of the multicenter prospective skin cancer registry ADOREG
Anna-Sophia Leven, Triinu Peters, Luisa Sophie Rajcsanyi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 14, 2022
A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
Sied Kebir, Vivien Ullrich, Pia Berger, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 93) with videos related to
Sort By:
Page
of 10
European Journal of Cancer (Oxford, England : 1990)
|
February 26, 2026
Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG study
Lea Jessica Albrecht, Jana Garnier, Anne Zaremba, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2025
Long-Term Follow-Up of Real-World Adjuvant Anti-PD-1 Checkpoint Inhibition and Targeted Therapy in Patients With Stage III Melanoma
Georg C Lodde, Jessica C Hassel, Imke von Wasielewski, et al.
Ebiomedicine
|
September 3, 2023
Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma - analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM
Jan-Malte Placke, Mona Kimmig, Klaus Griewank, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 8, 2021
Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases
Anne Zaremba, Manuel Philip, Jessica C Hassel, et al.
EMBO Reports
|
September 26, 2022
MCU controls melanoma progression through a redox-controlled phenotype switch
Ioana Stejerean-Todoran, Katharina Zimmermann, Christine S Gibhardt, et al.
Nature Cancer
|
July 31, 2023
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma
Renáta Váraljai, Lisa Zimmer, Yahya Al-Matary, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 30, 2024
Early versus late response to PD-1-based immunotherapy in metastatic melanoma
Georg C Lodde, Fang Zhao, Rudolf Herbst, et al.
Journal for Immunotherapy of Cancer
|
June 10, 2022
Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG
Cindy Franklin, Peter Mohr, Leonie Bluhm, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 1, 2025
Sex-specific survival in advanced metastatic melanoma - a DeCOG study on 2032 patients of the multicenter prospective skin cancer registry ADOREG
Anna-Sophia Leven, Triinu Peters, Luisa Sophie Rajcsanyi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 14, 2022
A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
Sied Kebir, Vivien Ullrich, Pia Berger, et al.
Page
of 10